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Cathepsin H is a lysosomal glycoprotein and a member of the
cysteine proteinase family, as are cathepsins B and L (Kirschke
et al, 1998). These proteinases have been viewed traditionally as
simple mediators of lysosomal protein degradation (Chapman
et al, 1997), although studies have also demonstrated their
temporal regulation during development (Mathur et al, 1997) and
their specificity of expression with cell type and function
(Taniguchi et al, 1993). Cathepsin H is easily distinguished from
cathepsins B and L by its unique aminopeptidase activity (Guncar
et al, 1998) while the latter are better described as endopeptidases
(Kirschke et al, 1998).
Cathepsins have been particularly well described for their
abnormal expression patterns during cancer development
(Iacobuzio-Donahue et al, 1997; Leto et al, 1997). Cancer growth
and progression require proteolytic enzymes as necessary tools for
invasion and metastasis (Liotta and Stetler-Stevenson, 1991).
Recent findings suggest that various types of cysteine proteinase
have specific roles in apoptosis (Nitatori et al, 1996), the cell cycle
(Fu et al, 1998), MHC class II immune responses (Lafuse et al,
1995) or activation of growth factors and hormones (Mithofer
et al, 1998). Matrix metalloproteinases, serine and aspartic
proteinases, as well as cysteine proteinases, contribute to the
degradation of basement membranes and the extracellular matrix
(Gabrijelcic et al, 1992) during cancer progression. Evidence
has now accumulated that these proteinases may also serve as
prognostic indicators in solid cancers (Schwartz, 1995).
While fewer studies on cathepsin H in cancer have been done
compared to other cathepsins, cathepsin H protein has been found
to be significantly elevated in sera of breast cancer patients and in
breast cancer tissue extracts (Gabrijelcic et al, 1992). Cathepsin H
has also been detected by immunohistochemistry in primary
melanoma and metastatic lesions compared to pigmented naevi or
normal skin (Kageshita et al, 1995). It has been found to be
secreted, in its precursor form, from the human melanocytic cell
line, G361, into culture media (Tsushima et al, 1991). Elevated
cathepsin H serum levels, measured by enzyme-linked
immunosorbent assay (ELISA) in patients with melanomas corre-
lated with the presence of metastases and with decreased patient
survival (Kos et al, 1997). In patients with gliomas, elevated
cathepsin H also correlated with increasing malignant potential of
the cancers (Sivaparvathi et al, 1996).
In contrast, decreased cathepsin H expression has been reported
in some cancers. For example, cathepsin H, detected by ELISA, in
squamous cell carcinomas of the head and neck, was found to be
higher in normal compared to malignant cell extracts (Kos et al,
1995), with high normal cathepsin H concentrations correlating
with longer disease-free survival (Budinha et al, 1996). Cathepsin
H enzyme activity was also diminished in polycystic kidney
disease, a non-cancer condition, characterized by hyperprolifera-
tion (Hartz and Wilson, 1997). Still other studies have measured
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atic cancer cells compared to less differentiated cancer cells
(Paciucci et al, 1996). These studies suggest a complex association
between cathepsin H and altered cell growth patterns.
Reported differences in cathepsin H expression patterns in
various cancers may reflect highly specific functions for cathepsin
H in different tissues and at different cancer stages. Our current
studies of cathepsin H-specific aminopeptidase activity, cathepsin
H protein forms and immunohistochemistry in matched pairs of
colorectal cancers and control mucosae, were designed to explore
further the specificity of this proteinase with respect to cancer
stage and site in colorectal cancer progression.
MATERIALS AND METHODS
Tissue specimens
Tissues were collected at surgery as colectomy specimens at the
Mallory Institute of Pathology or through the Cooperative Human
Tissue Network (CHTN), with cancer samples and normal mucosa
obtained from each patient. Matched normal mucosa, resected at a
minimum of 5–10 cm from the cancer tissue, was used as the
control tissue as colorectal cancers originate from the epithelium
of the colon mucosa. Care was taken to eliminate necrotic portions
from the cancers. In addition, fat, serosa and muscle layers were
separated from the normal mucosa epithelium prior to freezing.
All tissues collected were stored frozen at – 80°C until needed for
experiments.
Patients
Seventy-seven colorectal cancer patients were included in our
cathepsin H expression study. Table 1 summarizes information on
patient characteristics.
Dukes’ classification
Before reaching the laboratory, cancer tissues were staged by
pathologists at the Mallory Institute of Pathology, or at CHTN-
associated hospitals, according to the Dukes’ classification system
(Dukes, 1932) as modified by Turnbull et al (1967). Dukes’ A
cancers are defined as those confined to the bowel wall, Dukes’ B
cancers as those spread through the wall without involvement of
lymph nodes, Dukes’ C cancers as having metastasized to the
regional lymph nodes regardless of the extent of bowel wall pene-
tration, and Dukes’ D cancers as having metastasized to distant
sites.
Tissue extractions
Tissue extractions were carried out concomitantly for each cancer
tissue and matched normal mucosa, as previously described
(Iacobuzio-Donahue et al, 1997). Tissue samples (60–80 mg in
400–500 ml double-distilled deionized water) were homogenized
using a Polytron homogenizer. The homogenized tissues were
sequentially frozen three times in a methanol/dry ice bath (approx-
imately –79°C) and thawed three times in warm water (approxi-
mately 37°C), in order to rupture the cells and release their
contents. Centrifugation was carried out for 50 min at 4°C at
12 000 rpm (17 210 g) in a Sorvall 5B centrifuge. The super-
natants, containing extracted soluble protein, were removed and
stored at – 80°C until needed. In order to control for possible
alterations of cathepsin H protein during the extraction procedure,
the case no. 64 cancer sample was extracted independently 
either in the presence of four different inhibitors or, using 
standard procedure, in water (ddH2O). The inhibitors were E-64
(100 mM,  L-trans-epoxysuccinylleucylamido(4-guanidine)butane
(Sigma, St Louis, MO, USA); phenylmethylsulphonyl fluoride
(PMSF; 200 mM) (Sigma, St Louis, MO, USA); EDTA (10 mM) or
pepstatin (1 mg ml–1) (Sigma). All five extraction samples were
then compared for variations in cathepsin H banding patterns on
Western blots.
Cathepsin H enzyme activity assay
The activity of cathepsin H was determined against the specific
synthetic substrate L-Arg-MNA (Sigma; and Enzyme System
Products, Dublin, CA, USA) to take advantage of the specific
aminopeptidase activity of cathepsin H, that distinguishes it from
other cysteine lysosomal enzymes, such as cathepsins B and L
(Schwartz and Barrett, 1980; Guncar et al, 1998). Tissue extracts
(10–20 ml per assay) were pre-incubated in assay buffer (0.1 M
MES-EDTA buffer, 1 mM dithiothreitol (DTT), pH 6.8) at 37°C
for 5 min, using a modification of methods described by Schwartz
and Barrett (1980). To start the assay reaction, 1 mM substrate
(L-Arg-MNA) was added to buffer plus tissue extract, samples
incubated at 37°C for 10 min, and then reaction stopped by addi-
tion of 50 ml 1 N hydrochloric acid (HCl) in 2% Triton X-100. Fast
blue (O-dianisidine tetrazotized) (Sigma) (0.5 mg ml–1) was added
and colour developed for 10 min before absorbance was read at
520 nm in a Gilford spectrophotometer. Protein content (mg ml–1)
was determined for each tissue extract by the method of Lowry
et al (1951), using bovine serum albumin as standard. Enzyme
activity in nmol of substrate hydrolysed per min ml–1 was always
normalized for protein content, with final specific activity defined
as nmol of substrate hydrolysed per min mg–1 of protein (nmol
min–1 mg–1). Cathepsin H was also tested in the presence and
absence of the inhibitor puromycin at both 1 mM (Schwartz and
Barrett, 1980) and 10 mM concentrations (Claus et al, 1998), to
control for the specificity of the activity measured in tissue
homogenates (Kirschke et al, 1998). Cathepsin H activity was
also measured in the presence and absence of E-64 (L-trans-epoxy-
succinyl-leucylamido(4-guanidino)butane) (100 mM in dimethyl
sulphoxide) as described by Barrett et al (1982).
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Table 1 Patient characteristics
Characteristic na
Patients 77
Male/female 49/27
Median age in years (range) 70 (36–86)
Stage
A1 2
B3 0
C2 0
D1 5
Tumour location
Right 38
Left 36
aSubtotals do not always add up to the total number of patients studied,
because of incomplete patient information for some cases.Western blotting assay
Colorectal cancer and matched mucosa extracts (30 mg sample
protein per lane) were added to a denaturing buffer (2% sodium
dodecyl sulphate (SDS), 5% b-mercaptoethanol, 10% glycerol,
62.5 mM Tris, pH 6.8) and boiled for 5 min. The samples were then
run on a 16% polyacrylamide minigel (Novex, San Diego, CA,
USA) for 3.5 h at 70 V on a Biorad Mighty Small 260 apparatus.
Rainbow size markers (Amersham, Arlington Heights, IL, USA)
were run on each gel (5 ml per slot) as MW standards. After elec-
trophoresis the gel proteins were transferred overnight to a nitro-
cellulose membrane (Schleicher and Shuell, Keene, NH, USA) in
a Biorad Transblot Apparatus at 100 mAmp (Towbin et al, 1979),
containing transfer buffer (25 mM Tris, 192 mM glycine, 20%
methanol, 1% SDS). After transfer, the membrane was washed in
TBST buffer (0.25 mM Tris, 125 mM sodium chloride (NaCl),
0.05% Tween-20), and then blocked with 5% milk (dry milk) in
TBST, before incubating with cathepsin H primary antibody
overnight (Athens Research and Technology, Athens, GA, USA)
that had been diluted 1:2000 in 5% milk in TBST. Blots were
washed again with 5% milk in TBST and then with TBST before
incubation with horseradish peroxidase conjugated secondary anti-
body (Sigma) for 1 h. Blots were then washed for 3 h in 5% milk
in TBST and then three times for 10 min in TBST. Proteins were
detected by using an enhanced chemiluminescent system (NEN,
Boston, MA, USA).
Laser densitometry
Relative quantities of cathepsin H protein forms in 43 paired
extracts detected on film, following Western blotting, were visu-
ally assessed by three independent observers and a C/N ratio deter-
mined for each case. Confirmation of these C/N ratios were then
determined for 34 cases by quantitative laser densitometry, using a
Molecular Dynamics Personal Densitometer SI.
Immunohistochemistry
Archival paraffin-embedded tissue sections of colorectal carci-
nomas were obtained from the Mallory Institute of Pathology.
Tissue sections (5 microns) were sliced using a microtome,
mounted on poly-lysine-coated clean glass slides, dewaxed in
xylene and hydrated in graded concentrations of ethanol.
Endogenous peroxidase was blocked with 0.3% hydrogen
peroxide in methanol after which slides were blocked 5 min with a
1:20 dilution of casein. Next, slides were incubated with a 1:2500
dilution of polyclonal rabbit anti-human liver cathepsin H anti-
body (Athens Research and Technology) diluted in 0.05 M Tris
buffer, pH 7.4, for 30 min at room temperature, followed by a
5 min incubation at 37°C with biotinylated secondary antibody
(BioGenex), then a 5-min incubation at 37°C with peroxidase-
conjugated streptavidin label (BioGenex). Slides were washed
three times with 0.05 M Tris buffer, pH 7.4, after each incubation.
Colour was developed using DAB (3-3¢ diaminobenzidine tetrahy-
drochloride). Haematoxylin was used to counterstain the slides.
For control slides, the primary antibody was replaced by 0.05 M
Tris buffer, pH 7.4. Positive or negative expression and subcellular
localization of cathepsin H protein in tissue sections was evaluated
by two independent observers. Intensity was scored on a scale of
0–4, with 0 equal to negative expression and 4 equal to strongly
positive expression.
Statistical analysis
Summary data are expressed as the mean ± standard deviation
(s.d.) unless otherwise indicated. To compare data with two means,
the Student’s t-test for the difference between means was used. To
test whether a population mean was different from 1, a one-sample
t-test was used (Dawson-Saunders and Trapp, 1994). To test for
the association between two variables, linear regressions with
calculation of a correlation coefficient have been used. To compare
differences between distributions, the c2 test has been used with a
Fisher exact test correction where needed. To compare medians of
two groups, the Wilcoxon rank sum test was used. Confidence
limits were also calculated in order to determine the mean differ-
ence in our paired study between cancers and control mucosae
activities, by subtracting the cathepsin H-specific activity for each
control mucosa from the cathepsin H-specific activity for each
matched cancer tissue, and then calculating a mean difference for
these multiple individual calculations and a mean standard error of
the difference, according to the standard formula d ± (t value)(SEd)
= confidence interval (Dawson-Saunders and Trapp, 1994).
Two-tailed probability values of 0.05 or less were considered
significant, unless a one-tailed probability test is indicated.
Calculations were performed using the statistical package,
GraphPad InStat (GraphPad Software, version 1.11a, C
Haudenschield, 1990) and confirmed by use of Microsoft Excel
5.0 (Microsoft Corp) or ‘Primer of Biostatistics’, Version 4.0
(McGraw-Hill, 1996).
RESULTS
Our analyses of cathepsin H aminopeptidase activity and protein
banding patterns were carried out on matched pairs of colorectal
cancer and control mucosa tissue samples. The 77 cases analysed
included 12 Dukes’ A cancers, 30 Dukes’ B cancers, 20 Dukes’ C
cancers and 15 Dukes’ D cancers (Table 1), each with patient-
matched normal mucosa.
Cathepsin H mean aminopeptidase activity and mean
C/N ratio
Cathepsin H demonstrated a mean specific aminopeptidase
activity of 8.46 ± 5.2 nmol min–1 mg–1 in 77 normal mucosa tissues
and an activity of 10.9 ± 8.3 nmol min–1 mg–1 in the 77 matched
colorectal cancer specimens from the same patients. This differ-
ence in cathepsin H activity between cancer tissues and control
mucosa was highly significant (P = 0.003) (Figure 1A).
Calculation of the 95% confidence interval for the mean increase
in cathepsin H enzyme-specific activity for 77 pairs of cancer and
matched normal mucosa indicated a range of values between
1.3 nmol min–1 mg–1 and 3.76 nmol min–1 mg–1, an interval that
does not include a zero value, confirming a significant increase in
cathepsin H enzyme activity in colorectal cancers versus normal
mucosa.
Cathepsin H specific activity in each cancer was also compared
to the matched mucosa to determine an individual C/N ratio for
each matched tissue pair. The mean cathepsin H C/N ratio for all
77 cases analysed was 1.43 ± 0.77 (P < 0.0001), indicating that
cathepsin H activity was, on average, 1.4-fold higher in cancers
than in matched normal mucosa (Figure 1B).
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As a further means of assessing the changes in cathepsin H
aminopeptidase activity in cancers compared to matched normal
mucosa, we ascertained the percentage of cases that demonstrated
a ‘high’ C/N ratio, defined as C/N ³ 1.5, thus including only those
cases having a C/N ratio above the mean increase for all cancers
assayed (mean C/N = 1.4; P = 0.0001). By definition such cancers
have an increase in activity at least 50% over normal, or the equiv-
alent of an additional cathepsin H gene. Of 77 matched pairs
analysed, 28 cases (36%) demonstrated a C/N ratio ³ 1.5. The
mean C/N ratio for these 28 cases was 2.22 ± 0.7, while the mean
C/N ratio for the remaining 49 cases (64%) was 0.98 ± 0.26 (P =
0.0001), suggesting that the increase in cathepsin H activity in all
cases could be explained primarily by elevated cathepsin H
activity levels in 1/3 of the cancers analysed, while the remaining
2/3 of the cancers demonstrated little change in cathepsin H
activity levels. We subsequently compared activity levels in the
respective normal and cancer tissues for cases with C/N ratios
³ 1.5 compared to cases with C/N < 1.5. Cathepsin H enzyme
activity levels in normal mucosa specimens from patients with
either ‘low’ or ‘high’ C/N ratios were not statistically different
(7.5 ± 4.6 and 8.99 ± 5.46 nmol min–1 mg–1 respectively). These
normal mucosa activity levels were also indistinguishable from
cathepsin H activity levels in the cancers with ‘low’ C/N ratios
(7.9 ± 3.9 nmol min–1 mg–1), as graphed in Figure 1C. However,
cancers with ‘high’ C/N ratios demonstrated a mean cathepsin H
enzyme activity of 16.14 ± 10.9 nmol min–1 mg–1, more than twice
the activity in control tissues or in cancer tissues with ‘low’ C/N
ratios (P < 0.0001). These results provide evidence for two popu-
lations of colorectal cancers: those demonstrating cathepsin H
enzyme activity at least twice that of matched control mucosa and
those demonstrating no change in cathepsin H enzyme activity
compared to normal mucosa.
Cathepsin H enzyme activity: controls for assay
specificity
Proteinases able to hydrolyse single amino acid naphthylamide
substrates in mammalian cells include the metalloexopeptidase
arylamidases, a subclass of the cytosolic aminopeptidases
(Johnson and Hersh, 1990) and the cysteine proteinase cathepsin
H, the only known aminopeptidase of the mammalian lysosome
(Kirschke et al, 1998). Specificity of the assay was demonstrated
by measuring cathepsin H enzyme activity in the presence and
absence of two different concentrations of the inhibitor puromycin
(10 mM and 1 mM). At the 10 mM micromolar concentration,
puromycin is a strong inhibitor of cytosolic aminopeptidases
(Kirschke et al, 1998) but does not inhibit cathepsin H. However,
at the 1 mM concentration, puromycin generates a partial inhibi-
tion of cathepsin H (Schwartz and Barrett, 1980). Assays of
homogenates from six matched cancer and normal samples, two
tumour metastases and one adenoma showed no differences in
activity in the presence or absence of 10 mM puromycin, indicating
that the assay detected cathepsin H enzyme activity and not the
activity of cytosolic aminopeptidases. Assays of homogenates
from eight matched cancer and normal samples showed partial
inhibition of activity in the presence of 1 mM puromycin, with
cancer tissues showing 22.7 ± 9.97% inhibition (n = 8) and
matched normal tissues showing 26.0 ± 18.9% inhibition (not a
significant difference). This partial inhibition by 1 mM puromycin
was comparable to the 36% inhibition of purified cathepsin H by
1m M puromycin reported in the literature (Schwartz and Barrett,
1980).
Cathepsin H enzyme activity was also measured in the presence
and absence of 100 mM E-64 with no inhibition observed in either
normal or cancer tissues, again demonstrating the specificity of
our assay for cathepsin H activity. E-64 is a strong inhibitor of the
majority of cysteine proteinases, with the exception of the cysteine
proteinase cathepsin H, as reported in biochemical studies
(Katunuma and Kominami, 1995) and more recently confirmed by
the publication of the crystal structure of porcine cathepsin H
(Guncar et al, 1998).
Cathepsin H activity levels: correlation with Dukes’
stage
To determine whether cathepsin H enzyme activity levels
increased in a pattern related to cancer progression we calculated
the mean enzyme-specific activity for cancers at each Dukes’
stage and compared these activities to the mean specific activity
for cathepsin H in control mucosa. As graphed in Figure 2A,
cathepsin H demonstrated significantly elevated enzyme activity
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Figure 1 Cathepsin H enzyme-specific activity and C/N ratios in colorectal
cancer. (A) Cathepsin H enzyme specific activity was significantly elevated in
colorectal cancer compared to matched normal colon mucosa (n = 77;
P = 0.003, paired t-test) (B) The mean C/N ratio for 77 matched cancer and
normal colorectal cases was found to be significantly different from 1 (n = 77,
one-sample t-test). (C) Mean cathepsin H activity levels are graphed for
normal mucosa from either ‘low’ or ‘high’ C/N groups compared to mean
activity levels in cancers from ‘low’ or ‘high’ C/N groups. Cathepsin H activity
levels in cancers with C/N ratios ³ 1.5 were significantly elevated over mean
activity levels for any other group. ***P < 0.0001. NCT, normal colon mucosa;
CA, colorectal carcinomalevels in Dukes’ B and C stage cancers (P = 0.02, n = 30; and
P = 0.03, n = 20 respectively; one-tailed, unpaired t-test) but not
Dukes’ A or D stage cancers compared to enzyme activity levels in
normal mucosa.
To control for normal variation in cathepsin H activity levels in
individual control mucosa, paired sample measurements were then
utilized to derive average C/N ratios as an alternative measure of
changes in cathepsin H activity with cancer stage (see Figure 2B).
The C/N ratio for cathepsin H activity was most significantly
elevated in stage B (P = 0.006) and stage C cancers (P = 0.003).
Although Dukes’ D cancers showed an average increase greater
than that seen in Dukes’ B cancers, these late stage cancers were
also characterized by greater variability in cathepsin H expression
levels, so that the overall increase was not as significant.
Finally, we also calculated the percentage of cases at each
Dukes’ stage that demonstrated a ‘high’ or ‘low’ C/N ratio as well
as the average ratio at each stage for cathepsin H activity within
the ‘high’ or ‘low’ expressing groups. These results demonstrated
that the frequency of cases with C/N ³ 1.5 in Dukes’ C cases
amounted to 50%, while in the other Dukes’ stages it amounted
roughly to 30% (Figure 2C). For all ‘low’ cases, irrespective of
Dukes’ stage, the mean C/N ratio was the same, that is . 1.0.
However, for cases in the ‘high’ C/N ratio group an apparent
increase in mean C/N ratio was observed with cancer progression.
Thus for Dukes’ stage A cancers, the mean C/N ratio for cases
with ‘high’ C/N ratios was 1.75 ± 0.19 (n = 4) while the mean for
‘high’ C/N ratio cases for Dukes’ stage B was significantly higher
(P < 0.01, n = 9, unpaired Student’s t-test) and the mean C/N ratio
for Dukes’ stage D still higher (C/N = 2.76 ± 1.2, n = 5), although
the significance of this progressive elevation at stage D must be
confirmed with more observations. For each Dukes’ stage, cases in
the ‘high’ group had significantly higher C/N ratios than cases in
the ‘low’ C/N ratio group (P < 0.001).
Cathepsin H activity levels: correlation with cancer
location
In order to determine whether there was a correlation between
cathepsin H activity and location of cancers in the large intestine,
activity C/N ratios were analysed with respect to right-sided or
left-sided cancer location, as shown in Figure 3A. We found that
cancers resected from the left colon, including 19 sigmoid colon
cancers, four rectosigmoid junction cancers and 11 rectal cancers,
had a significantly higher mean C/N ratio (1.7 ± 0.8) than cancers
resected from the right colon, including 23 caecum cancers, two
ascending colon cancers and four transverse colon cancers
(P < 0.01). However, although the C/N ratios were not as high in
the right colon compared to the left colon, the mean C/N ratio for
cathepsin H activity levels for all cases located in the right colon
(n = 38) was still significantly different from 1 (1.23 ± 0.69,
P < 0.05).
To further assess the correlation between cathepsin H C/N ratios
and cancer location, we also determined the percentage of cancers
at each site that demonstrated a ‘high’ C/N ratio and found that
among the cases with C/N ratios ³ 1.5, 70% were resected from the
left colon (Figure 3B, P < 0.001).
Significant differences in cathepsin H expression for left-sided
versus right-sided cancers could be demonstrated not only by C/N
Cathepsin H expression in colorectal cancer 1321
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Figure 3 Cathepsin H C/N ratios and tumour progression. (A) C/N ratios for
77 matched pairs of colorectal cancer and normal mucosa. Dark columns
represent C/N ratios for left-sided cancers while light columns represent
cancers from the right colon. Cancers located in the left colon had
significantly higher C/N ratios than cancers from the right colon (P < 0.01)
The mean C/N ratio for all right-sided or left-sided cancers were also
significantly different from 1 (P < 0.05 and P < 0.0001 respectively). (B) The
percentage of cases with C/N ratio ³ 1.5 was significantly higher in left-sided
cancers by the c2 test (P < 0.001). (C) Mean cathepsin H C/N ratios in the left
colon and in the right colon sorted by Dukes’ stage. Dukes’ C stage
right-sided colon cancers had a mean C/N ratio significantly different from 1
(1.5 ± 0.7, n = 10, *P < 0.05). Dukes’ B and C left-sided colon cancers also
demonstrated C/N ratios significantly different from 1 (1.8 ± 0.5, n = 13,
***P < 0.0001 and 1.7 ± 0.7, n = 10, *P < 0.05 respectively)ratios but also by a direct comparison of mean enzyme-specific
activity levels for all cancers versus all normal mucosa at a given
colon location. Cathepsin H activity for normal mucosa of the
right colon (8.7 ± 5.2 nm min–1 mg–1 protein; n = 38) did not differ
from activity for normal mucosa of the left colon (8.3 ± 5.3 nm
min–1 mg–1 protein; n = 36). Cancers of the right colon also did not
demonstrate a significant increase in activity (9.3 ± 6.6 nm min–1
mg–1 protein; n = 38; P = 0.5) over control mucosa but cancers of
the left colon showed a highly significant increase in cathepsin
H-specific activity (12.9 ± 9.7 nm min–1 mg–1 protein; n = 36)
compared to control mucosa (P = 0.0006). The largest cancer
subsets followed these patterns as well, with left-sided sigmoid
cancers demonstrating a significant increase in cathepsin H
activity (14.8 + 11.3 nm min–1 mg–1 protein; n = 19) over normal
sigmoid mucosa (9.2 ± 6.5 nm min–1 mg–1 protein; P = 0.006)
while the increase detected in right-sided caecal cancers
(10.5 nm min–1 mg–1 protein; n = 23) versus normal caecal mucosa
(9.0 ± 5.4 nm min–1 mg–1 protein; P = 0.45) was not significant.
We subsequently determined whether cathepsin H expression
patterns for left-sided versus right-sided cancers would reflect the
same specificity for Dukes’ stage that had been observed for all
cases. Among the 74 cancers studied for location effects, those
resected from the left colon (n = 38) demonstrated similar distrib-
utions with respect to clinical stage to those from the right colon
(n = 36). Thus, Dukes’ C cancers from the right colon still demon-
strated the highest C/N ratio (1.52 ± 0.7, P < 0.05), compared to all
other right-sided cancers. In the left colon, both Dukes’ stage B
and C cancers demonstrated C/N ratios significantly different from
1 (P < 0.0001 and P < 0.05), as shown in Figure 3C. Thus, cancer
stage appeared to predict cathepsin H activity C/N ratios, irrespec-
tive of site, but the combination of stage and site was the best
predictor of elevated cathepsin H C/N ratios.
We have also used cathepsin H activity C/N ratios from every
case to calculate a mean C/N ratio for cancers from each of six
specific colorectal regions, as shown in Figure 4. While the mean
C/N ratio for cancers resected from the transverse colon was found
to be higher than the mean C/N ratio for cancers in the right colon,
the number of cancers in the transverse colon was too small to
determine whether the apparent stepwise increase in cathepsin H
expression from right colon to transverse to left was significant
(Figure 4).
Cathepsin H protein expression patterns on Western
blots
To confirm the results obtained by measuring cathepsin H activity
in colorectal cancer compared to normal matched mucosa,
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Transverse
1.52 ± 0.75 (n = 4)
Left
1.70 ± 0.80
(n = 36)
Rectum
1.37 ± 0.66
(n =11)
Right
1.23 ± 0.70
(n = 38)
Cathepsin H C/N ratios sorted by cancer sites
Tumour locations         n C/N  ratios
Right colon
Caecum 23 1.25 ± 0.77
Ascending 2 0.75 ± 0.28
Transverse 4 1.52 ± 0.75
Total right 38 1.23 ± 0.70*
Left colon
Sigmoid 19 1.80 ± 0.78**
Rectosigmoid 4 1.72 ± 0.47
Rectum 11 1.37 ± 0.66
Total left 36 1.70 ± 0.80***
All sites 74 1.45 ± 0.77***
Figure 4 Cathepsin H activity C/N ratios sorted by colorectal cancer sites.
Schematic drawing of the large intestine showing that cathepsin H C/N ratios
were lowest in the right colon (light grey), increase in the transverse colon
(medium grey) and were highest in the left colon (dark grey) Data were
summarized for six specific regions of the right or left colon and C/N ratios
shown for each region together with summary data. In addition to 34 left-
sided cancers sorted by subgroups, the total of 36 left-sided cancers also
included one cancer designated from the ‘descending’ colon and one cancer
designated simply as ‘left’. The 38 right-sided cancers included one ‘hepatic
flexure’ cancer and eight cases simply termed ‘right colon’ cancers, as well
as the 29 right-sided cancers sorted by regional subgroups. Mean C/N ratios
for cathepsin H activity levels were significantly different from 1 for 38
colorectal cancers resected from the right colon (P < 0.05), 36 cancers from
the left colon (P < 0.0001) and 19 cancers of the sigmoid colon (P < 0.001),
as well as for the total of 74 colorectal cancers studied by tumour location
(P < 0.0001)
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N       C N       C N       C
123
31
29
31
29
22
31
29
B C
A
Figure 5 Cathepsin H protein banding patterns: Western blots of matched
cancer/normal pairs and purified cathepsin H protein controls. (A) Matched
colorectal mucosa (N) and cancer (C) tissue extracts (30 mg total soluble
protein/lane) from three independent cases demonstrated cathepsin H
protein bands at 31 and 29 kDa. Decreased expression of the 31 kDa band
was observed in the majority of colorectal cancers compared to the matched
colon mucosa samples in conjunction with frequent increases in expression
of the mature single-chain 29 kDa form of cathepsin H. (B) A representative
matched pair of normal mucosa (N) and cancer (C) samples are shown,
demonstrating the typical 31 plus 29 kDa bands in normal mucosa,
decreased expression of the 31 kDa band in cancer plus the appearance of
the 22 kDa heavy-chain of two-chain mature cathepsin H in the cancer,
possibly reflecting increased cathepsin H protein processing in the cancer.
(C) Four types of purified human liver cathepsins (100 ng per lane), including
cathepsin B (CB), cathepsin D (CD), cathepsin H (CH) and cathepsin L (CL)
were probed with the cathepsin H polyclonal antibody(Athens Research
Laboratories, Athens, GA, USA) to confirm antibody specificitycathepsin H protein banding patterns were also analysed by
Western blotting studies of 43 paired extracts that had already been
assayed for cathepsin H activity levels. The 43 cases included five
Dukes’ A stage cancers, 15 Dukes’ B cancers, 13 Dukes’ C
cancers and 10 Dukes’ D cancers.
In normal mucosa and in cancer tissues cathepsin H was
detected as three protein bands measuring approximately 31, 29
and 22 kDa (Figure 5). The frequency and levels of expression for
these cathepsin H protein forms differed between normal mucosa
and cancer tissues.
Expression of the 31/29 kDa cathepsin H protein
doublet
The most typical cathepsin H banding pattern for control mucosa
was a protein doublet with bands measuring approximately 31 and
29 kDa (Figure 5A). This doublet was significantly more common
in normal mucosae (41/43) than in corresponding cancer speci-
mens (28/43) (P = 0.001). A quantitative change occurred in the
cancers, with decreased levels of the 31 kDa cathepsin H band
detected in 90% of the 43 cancers studied compared to the
matched normal mucosa. In some cancers the 31 kDa cathepsin H
band was undetectable, even when films of the Western blot data
were overexposed. For 28 cases that expressed the 31 kDa band at
detectable levels in both cancer and matched normal samples, the
C/N ratio for this form of cathepsin H protein was 0.47 ± 0.49. In
contrast to the loss of expression of the 31 kDa band in cancers,
most cancers demonstrated the clear presence of a 29 kDa mature
single-chain form of cathepsin H at levels that were usually
unchanged or increased compared to the normal mucosa.
Expression of the 22 kDa cathepsin H heavy-chain band
Up-regulation of a 22 kDa protein band was also observed in
cancers versus matched mucosa samples detected on Western
blots. This cathepsin H form is classically described as the 22 kDa
heavy-chain of mature, active two-chain cathepsin H (the corre-
sponding 6 kDa light-chain of this form is not detected due to gel
running conditions), derived from the 29 kDa single-chain form by
further processing. This 22 kDa cathepsin H protein (Figure 5B),
was detected in 72% of the cancer tissues (31/43) compared to
53% of control mucosa samples (23/43 tissues). For those 23 cases
that demonstrated this band in both matched cancer and normal
mucosa specimens, expression levels in the normal mucosa were
often very weak, with a resulting C/N of 2.9 ± 1.5 (P < 0.0001). A
comparison of the typical normal versus cancer pattern for the
22 kDa heavy-chain band of cathepsin H can be seen in Figure 5B.
C/N ratios for the 23 cases in which this protein form was present
in both control mucosa and cancers, were found to be highest in
Dukes’ B (3.1 ± 1.6, n = 10) and Dukes’ C (3.2 ± 1.8, n = 7)
compared to Dukes’ A or D stage cancers (2.1 ± 1.0, n = 3 and
1.8 ± 0.5, n = 3 respectively), with C/N ratios for stages B and
C significantly different from 1.0 (P < 0.005 and P < 0.02
respectively).
Cathepsin H: controls for protein banding studies
As seen in Figure 5C, the specificity of the cathepsin H antibody
was confirmed by detection of purified human liver cathepsin H
protein but not of purified human liver cathepsins B, L or D
proteins that were run side by side and probed simultaneously, on a
single Western blot, with the cathepsin H antibody.
We also determined whether the alterations in cathepsin H
banding patterns in cancer samples might be due to increased
proteolytic processing of cathepsin H occurring in cancer
homogenates following extraction. However, identical cathepsin H
banding patterns were detected by Western blotting for five inde-
pendent extractions of the same cancer tissue, whether the extrac-
tion was done in distilled, deionized water or in the presence of
any of four inhibitors for different classes of proteolytic enzymes
(data not shown).
Cathepsin H: correlation of single-chain mature form
with enzyme activity
To test for a correlation between changes in cathepsin H activity
levels and cathepsin H protein levels in cancer samples compared
to normal mucosa, C/N ratios for cathepsin H activity were
compared to C/N ratios for cathepsin H protein levels as detected
in individual cathepsin H protein bands on Western blots of 43
matched extract pairs. These comparisons of activity C/N ratios
with protein C/N ratios for individual cases revealed that the
common decrease in the 31 kDa band, although a very good
marker for cancer, did not correlate with cathepsin H aminopepti-
dase activity levels. However, as seen in Figure 6, a significant
correlation was observed between C/N ratios for cathepsin H
activity and the corresponding C/N ratios for the 29 kDa mature
single-chain form of cathepsin H in these same cases (r = 0.56;
P < 0.001). Typically, cases with high cathepsin H activity C/N
ratios (C/N ³ 1.5) also demonstrated significantly increased C/N
ratios for the 29 kDa cathepsin H protein band. However, there
were exceptions to this rule, as the percentage of cases demon-
strating a C/N ³ 1.5 for the 29 kDa protein band (21% of cases
analysed) was less frequent than the percentage of cases demon-
strating an activity C/N ratio ³ 1.5 (36%). For cases with high
activity C/N ratios but without a marked increase in the 29 kDa
band, the majority of cases (8/11) demonstrated a high C/N ratio
for the 22 kDa cathepsin H protein form, suggesting that this more
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Cathepsin H activity C/N ratios
Figure 6 Scatter plot correlation analysis of C/N ratios for cathepsin H
enzyme-specific activity versus C/N ratios for the cathepsin H 29 kDa mature
protein form. The C/N ratios for cathepsin H activity correlated with the C/N
ratios for the 29 kDa mature cathepsin H protein form with each assay done
on the identical extracts from 43 cancer/normal tissue pairs. The slope for
this comparison was significantly different from 0, with r = 0.56 and P < 0.001fully processed form of cathepsin H also contributes to cathepsin
H aminopeptidase activity, as previously reported (Nishimura
et al, 1995).
Cathepsin H protein: correlation with site
The sample of cases studied for cathepsin H protein expression
patterns included 20 right-sided cancers and 23 left-sided cancers.
The mean C/N ratio for the 29 kDa cathepsin H mature protein in
left-sided cancers (1.4 ± 0.9) was also found to be significantly
higher than the mean C/N ratio for the 29 kDa cathepsin H protein
in right-sided cancers (0.9 ± 0.5) (P < 0.05).
Cathepsin H immunohistochemistry
Cathepsin H protein content and cellular localization were
analysed by immunohistochemical staining of tissue sections for
seven colorectal cancer cases. For both normal colon mucosa and
colorectal carcinoma sections, cathepsin H protein was primarily
localized to the epithelial cells, although staining of macrophages
was also seen. Cathepsin H staining in normal mucosa showed a
punctate pattern typical of lysosomal localization, while carci-
nomas demonstrated a fine granular, more diffuse cytoplasmic
staining. Cathepsin H protein staining was elevated in cancer
epithelial cells when compared to control mucosa (present on
slides for five of seven cases analysed) or to the stroma, particu-
larly for those cases with high C/N ratios for cathepsin H activity.
However, comparative statistical analyses of immunohistochem-
ical data versus activity data on the same cases will require much
larger sample sizes. Immunohistochemical staining for cathepsin
H in a Dukes’ C stage cancer is shown in Figure 7. This case, that
had a C/N ratio of 2.9 for cathepsin H activity, demonstrated
staining of the cancer epithelium, with intensity of staining scored
as +3 to +4, while stroma surrounding the tumour epithelium
was essentially negative for cathepsin H staining, except for
macrophages (not seen in this Figure).
DISCUSSION
Studies of melanomas, squamous cell carcinomas, gliomas, breast
and pancreatic carcinomas have shown altered expression of
cathepsin H by immunohistochemistry or enzyme-linked
immunosorbent assays (ELISA) (Gabrijelcic et al, 1992; Budinha
et al, 1996; Paciucci et al, 1996; Sivaparvathi et al, 1996; Kos et al,
1997). However, few studies have analysed cathepsin H expres-
sion in a large set of matched pairs of colorectal cancers and
mucosa by activity assays or Western blots.
Our study has demonstrated significant increases in cathepsin H
activity levels in colorectal cancer, alterations in cathepsin H
protein banding patterns, as well as localization of the protein in
the tumour epithelial cells. Particularly significant increases in
cathepsin H expression in Dukes’ B and C stage carcinomas
suggest a correlation between elevated cathepsin H activity and
the processes of local or lymph node invasion by colorectal cancer.
Increases in cathepsin H protein content in melanomas (Kos et al,
1997) and in enzyme activity and protein content in gliomas
(Sivaparvathi et al, 1996) also correlated significantly to the
malignant potential of these cancers.
Our cathepsin H activity data also indicate that two different
populations of colorectal cancers may exist, with one-third of all
cases characterized by high cathepsin H C/N ratios (C/N ratios
³ 1.5) and the remaining two-thirds having no significant change
in cathepsin H activity levels (C/N ratios . 1). Although one
previous study of five colorectal cancers and matched mucosa
homogenates showed increased cathepsin H enzyme activity in the
cancer extracts, the results were not statistically significant,
possibly due to sample size (Keppler et al, 1988). Different subsets
of colorectal cancers with very different cathepsin H expression
levels may also exist, due perhaps to a site-specific role for
cathepsin H in colorectal cancers, as we have observed that activi-
ties were highest and most frequently elevated in cancers from the
left portion of the large intestine.
Marked differences exist between cancers of the left and right
colon. Right-sided cancers are preferentially fungating, protruding
into the lumen as cauliflower-like masses, while left-sided cancers
tend to directly penetrate into the bowel wall (Rubin and Farber,
1994). Despite being more easily visualized by colonoscopy than
cancers from the right colon, ulcerating tumours of the distal left
colon are often diagnosed at a later stage and characterized by
worse prognoses (Wolmark et al, 1984; Rubin and Farber, 1994).
Left-sided tumours have significantly higher p53 overexpression
or mutation rates (71.4–67%) than right-sided tumours
(42.1–22%) (Breivnik et al, 1997; Lenz et al, 1998), while
microsatellite instability (MIN) is almost exclusively associated
with cancers of the proximal (right) colon (Breivnik et al, 1994,
1997). Furthermore, K-ras gene mutations, present in 40–60% of
colorectal carcinomas, are negatively associated with the presence
of MIN (Breivnik et al, 1994). Thus, it is possible to hypothesize
that either K-ras mutations or high expression of the tumour
suppressor gene p53 might correlate with increased activity of the
cysteine proteinase cathepsin H in the left colon. Variations in
cathepsin H expression with cancer site may reflect the different
genetic pathways described for colorectal cancers in left versus
right colon. Correlations between these molecular markers and
cathepsin B and L activities in colorectal cancers have already
been reported (Iacobuzio-Donahue et al, 1996; Kim et al, 1998).
A comparison of our cathepsin H activity data for clinical stage
and site confirmed that both variables could be related to elevated
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Figure 7 Cathepsin H immunohistochemical staining in colorectal cancer.
Cathepsin H protein expression in a Dukes’ C stage cancer is shown, as
detected on a paraffin-embedded section incubated with a 1:2500 dilution of
anti-human cathepsin H antibody and staining developed using a biotin-
streptavidin label, followed by a haematoxylin counterstain. This case
demonstrates staining of the cancer epithelium, with intensity of staining
scored as +3 to +4, while stroma surrounding the tumour epithelium was
essentially negative for Cathepsin H staining. Cathepsin H protein is seen to
be located diffusely throughout the cytoplasm in the form of fine granulescathepsin H C/N ratios. Irrespective of site, C/N ratios were
increased most frequently in colorectal cancers invading the bowel
wall and spreading to the lymph nodes (Dukes’ B and C cancers),
although the more aggressive left-sided colon cancers had the most
marked expression of cathepsin H. Notably, a higher frequency of
node-positive cancers is also found for cancers of the left colon
(Wolmark et al, 1984).
Our research has also provided new information on changes in
cathepsin H protein forms in cancer compared to normal tissue.
Traditionally three cathepsin H forms are described, including a
41 kDa proform, a 28 kDa mature single-chain form and a two-
chain mature form consisting of the 22 kDa heavy-chain plus a
6 kDa light-chain of cathepsin H (Kirschke et al, 1998). In addi-
tion, unusual cathepsin H molecular forms have been reported for
a cancer cell line (Waguri et al, 1995) and for polycystic kidney
disease (Hartz and Wilson, 1997). Our Western blot data on
cathepsin H protein bands has revealed a cathepsin H protein
doublet at 31 and 29 kDa, present in 41/43 (95%) normal colon
mucosa samples. A comparable cathepsin H protein doublet was
detected on Western blots of normal and malignant brain tissues
(Sivaparvathi et al, 1996). Our data indicate that reproducible
changes in the expression of this protein doublet provide the most
consistent indication of altered cathepsin H expression in
colorectal cancers. Loss or down-regulation of the 31 kDa
cathepsin H protein band occurred in 90% of the cancers analysed,
irrespective of cancer stage or site. Since this decrease in the
31 kDa band in cancers is much more common than the significant
increase in cathepsin H activity measured in 1/3 of the cancers, it is
not yet clear how the 31 kDa band contributes to normal function
nor how cathepsin H function changes with the loss of this band in
cancers.
Conceivably, the 31 kDa cathepsin H protein band may repre-
sent a protein intermediate that is converted to the 29 kDa form
during processing of cathepsin H zymogen. In fact, a transient
cathepsin H of 30 kDa, present during the generation of a mature
28 kDa single-chain cathepsin H has been described (Nishimura
and Kato, 1987). A higher rate of cathepsin H processing by
proteolytic clipping in colon cancer cells may explain the consis-
tent down-regulation of the 31 kDa band in cancers as compared to
the matched mucosae. Our control extractions in the presence of
different proteinase inhibitors indicated that any such processing
events would have to occur in the cancer prior to extraction rather
than during or after the extraction process.
For that subset of colorectal cancers, particularly Dukes’ B and
C stage cancers of the left colon, in which there was a significant
increase in cathepsin H activity, the activity increase correlated
with increased amounts of the 29 kDa single-chain cathepsin H
protein form or alternatively, with increased expression of the
22 kDa heavy chain of two-chain mature cathepsin H. These data
suggest again that the cathepsin H aminopeptidase activity
measured in our enzyme assay are dependent on expression levels
of more fully processed cathepsin H forms, including the 29 kDa
mature single-chain and the mature two-chain form, represented
by the 22 kDa band, rather than on the 31 kDa cathepsin H protein.
Nishimura and colleagues (1995) have reported a particularly
marked relationship between the presence of the 22 kDa cathepsin
H band and higher cathepsin H enzyme-specific activity as
measured in two distinct pools of cathepsin H protein isolated
from rat liver lysosomes.
Changes in cathepsin H expression were also shown by
immunohistochemical assays to be associated with increased
cathepsin H protein staining in carcinoma compared to normal
mucosa, with increased protein content detected primarily in
cancer epithelial cells, rather than stromal cells. A shift in
cathepsin H staining from a more punctate pattern in normal
mucosa, typical of lysosomal localization, to a fine granular, more
diffuse cytoplasmic staining in carcinomas was also observed,
similar to shifts in localization reported for cathepsin B protein
staining of colorectal cancers (Iacobuzio-Donahue et al, 1997).
Our results on cathepsin H expression in colorectal cancers indi-
cate both similarities and differences to the cancer-related changes
observed for cathepsins B and L in these same colorectal cancer
cases (Sheahan et al, 1989; Shuja et al, 1991; Iacobuzio-Donahue
et al, 1997). Cathepsin B and L activities were most significantly
and frequently elevated in Dukes’ A and B cancers in contrast to
cathepsin H activity, which was most elevated in Dukes’ B and C
stage cancers. Western blot studies of protein patterns for
cathepsin B (Iacobuzio-Donahue et al, 1997) and cathepsin H (this
study) have supported activity analyses but have also revealed
reproducible changes for both markers in the protein forms
expressed in cancers versus normal mucosa. For both cathepsin B
and cathepsin H, a specific change in protein banding pattern was
the most consistent indication of malignancy, irrespective of stage,
while changes in activity or protein expression levels were more
specifically related to stages of cancer progression.
Although Dukes’ classification remains a powerful predictor of
final outcome for colorectal cancer patients (Dukes, 1932; Deans
et al, 1992), the traditional clinicopathological predictors are not
yet fully successful at predicting recurrence and survival risks for
patients with Dukes’ stage B and C cancers (Liefers et al, 1998).
Our data on cathepsin H suggest that this new proteinase marker
might be particularly useful in defining Dukes’ B and C stage
cancers and in distinguishing subsets of cancers at a given site.
Thus, we are currently analysing cathepsin H expression with
respect to patient prognoses.
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